With recent successes in gene replacement therapy, scientists are enthused about studying how genetic variants play a part in age-related macular degeneration (AMD). Previous research has identified 34 small genomic regions (“loci”) on the DNA molecule and 52 genetic variants (mutations) within those loci that are associated with AMD. Variants can regulate certain genes to […]
New Website offers Patients Comprehensive, Educational Resources to Navigate Life with Age-Related Macular Degeneration Bausch + Lomb, a leading global eye health company, has announced the launch of SightMatters.com, a new educational online resource for people living with age-related macular degeneration (AMD). Bausch + Lomb launched the site to coincide with the start of AMD […]
Three anti-VEGF drugs are in clinical use for treatment of wet age-related macular degeneration (wAMD). These are Lucentis (ranibizumab), off-label Avastin (bevacizumab), and Eylea (ranibizumab). The rate of stroke from intravitreal injections of Lucentis was found in the early clinical trials to be 0.2% (1 of 525) in the combined group of patients compared to […]
A report at the Hawaiian Eye & Retina 2019 conference revealed another sustained-delivery drug, GB-102, for treatment of wet age-related macular degeneration (AMD). Graybug Vision’s ADAGIO study has now provided evidence that GB-102 can continuously inhibit activity of VEGF for several months. The treatment was well-tolerated in the study and found to be free of dose […]
Your story can help the Prevent Blindness organization improve vision treatment. Has your eye doctor prescribed a medication or a treatment to address your eye health condition? If so, have you ever found that your insurance company requires you to first try a generally cheaper and possibly less effective drug before they will approve the one […]
New research published this week in Clinical Epigenetics, has identified two new genes linked to the development of age-related macular degeneration (AMD). Led by Dr. Louise Porter at the University of Liverpool, the team identified genes that may become new targets for treatments. 44 human donor eyes were profiled for levels of DNA methylation (a […]
Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage […]
Kodiak Sciences Inc. has announced promising results from their Phase 1 clinical trial of KSI-301, a novel anti-VEGF compound for the treatment of age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Currently approved anti-VEGF drugs require several monthly “loading dosages” at the beginning of the treatment regimen. Twelve weeks after a single dose […]
Neovascularization is the term applied to growth of errant blood vessels into the retina. This can occur whenever the retina is compromised by diseases such as age-related macular degeneration, myopic degeneration, or diabetic macular edema. Neovascularization is initially identified during dilated eye examinations, the scheduling of which depends upon the patient’s initiative in acquiring and […]
Prevent Blindness marks January’s National Glaucoma Awareness Month by Offering Information and Resources for Patients and Caregivers Today, nearly three million people ages 40 and older have glaucoma, according to the Prevent Blindness report, “Future of Vision: Forecasting the Prevalence and Costs of Vision Problems.” Those numbers are projected to increase steadily as more baby […]